Skip to main content

Table 3 Multivariate logistic regression analysis using sRAGE to distinguish HFNO/MV and predict MV

From: Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COVID-19 disease severity and indicator of the need for mechanical ventilation, ARDS and mortality

Covariate HFNO/MV (n = 32/164) MV (N = 19/164)
OR (95% CI) p value OR (95% CI) p value
sRAGE* 1.782 (1.163–2.730) 0.008 1.389 (1.060–1.820) 0.017
SOFA Score ≥ 3 106.295 (17.102–660.653)  < 0.001 66.451 (7.343–601.396)  < 0.001
Age 1.031 (0.957–1.110) 0.419   
Comorbidity 1.228 (0.161–9.397) 0.843   
Male gender 4.687 (0.568–38.704) 0.151   
  1. *per 1000 pg/mL
  2. HFNO/MV high-flow nasal oxygen therapy or mechanical ventilation, sRAGE soluble receptor of advanced glycation end product, SOFA sequential organ failure assessment score